- Conditions
- Human Papillomavirus
- Interventions
- Participatory, Efficient
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 91
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Shigellosis
- Interventions
- Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo
- Biological
- Lead sponsor
- LimmaTech Biologics AG
- Industry
- Eligibility
- 8 Months to 50 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 0
- States / cities
- Not listed
- Conditions
- Rheumatic Diseases
- Interventions
- Hepatitis A vaccine, Diphtheria, pertussis, and tetanus booster vaccine
- Biological
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Northport, Alabama • Riverview, Florida • Boise, Idaho + 4 more
- Conditions
- Pertussis, Vaccination
- Interventions
- Survey
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Haemophilus Infections, Diphtheria, Tetanus, Polio, Pertussis
- Interventions
- DTaP-IPV/Hib
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- Up to 59 Months
- Enrollment
- 20,830 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 59
- States / cities
- Albany, California • Martinez, California • San Francisco, California + 56 more
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Leukapheresis, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Placebo Administration, Tetanus and Diphtheria Toxoids Adsorbed
- Procedure · Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Vaccines, Meningococcal Vaccines
- Interventions
- rLP2086 + MCV4 + Tdap, MCV4 + Tdap + saline, rLP2086 + saline
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 10 Years to 12 Years
- Enrollment
- 2,648 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 117
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Chandler, Arizona + 73 more
- Conditions
- Tetanus
- Interventions
- Adacel
- Biological
- Lead sponsor
- GCAM Inc.
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Eagle Pass, Texas • Laredo, Texas
- Conditions
- Pertussis
- Interventions
- Pentacel® (DTaP-IPV/Hib), Other Pertussis Vaccines
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- Up to 59 Months
- Enrollment
- 1,195 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin
- Conditions
- Vaccine Hesitancy
- Interventions
- INVEST
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Columbia, South Carolina
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Interventions
- Fluarix®, Boostrix®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 1,726 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 8 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
- Interventions
- vaccinated
- Biological
- Lead sponsor
- Neuroganics LLC
- Industry
- Eligibility
- 5 Years to 99 Years
- Enrollment
- 100,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Northglenn, Colorado
- Conditions
- Diphtheria, Pertussis, Tetanus
- Interventions
- Placebo, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Durham, North Carolina • Houston, Texas • Seattle, Washington
- Conditions
- Diphtheria, Tetanus, Pertussis
- Interventions
- DAPTACEL®: DTaP
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 649 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 22
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more
- Conditions
- Diphtheria, Pertussis, Tetanus
- Interventions
- Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Adult Influenza Vaccinations, Adult PPSV Vaccinations, Adult Tdap/Td Vaccinations
- Interventions
- Pillar 1: Convenient Vaccination Services, Pillar 2: Patient notification, Pillar 3: Enhanced Office Systems, Pillar 4: Motivation
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70,549 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Houston, Texas
- Conditions
- Childhood Cancer, Multiple Diseases
- Interventions
- Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- Ixekizumab, Boostrix®, Pneumovax®23
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
- Drug · Biological
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 39
- States / cities
- Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Interventions
- Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 15
- States / cities
- Jonesboro, Arkansas • Fountain Valley, California • Oakland, California + 12 more
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,797 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more
- Conditions
- Dermatitis Atopic
- Interventions
- Amlitelimab, Placebo, Tdap vaccine, PPS vaccine
- Drug · Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more
- Conditions
- Prevention of Meningococcal Disease
- Interventions
- MenACWY-CRM Vaccine, MenACWY-PS Vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 12 Months to 10 Years
- Enrollment
- 910 participants
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Oakland, California